GEN secures BEBO Foundation approval for Phase II PD trial

​GEN Pharmaceuticals has secured the BEBO Foundation approval for the assessment of ethics of biomedical research to initiate a Phase II clinical trial in the Netherlands of its new drug, SUL-238, for mitochondrial dysfunction in patients with PD.

The post GEN secures BEBO Foundation approval for Phase II PD trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

L&T Technology introduces AI lung digital twin for diagnostics
Sentynl and PRG partner for Progerinin licence
KORU Medical secures certification under EU MDR for infusion pump
J&J reports positive data for Erda-iDRS in bladder cancer
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us